Terns Pharmaceuticals, Inc.

NasdaqGS:TERN Rapporto sulle azioni

Cap. di mercato: US$586.0m

Terns Pharmaceuticals Crescita futura

Future criteri di controllo 0/6

Si prevede che gli utili di Terns Pharmaceuticals diminuiranno a 9.3% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 72.7% all'anno. Si prevede che l'EPS diminuirà di 2.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà -69.4% in 3 anni.

Informazioni chiave

-9.3%

Tasso di crescita degli utili

-2.4%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili23.6%
Tasso di crescita dei ricavi72.7%
Rendimento futuro del capitale proprio-69.4%
Copertura analitica

Good

Ultimo aggiornamento31 Oct 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Terns Pharmaceuticals: Another Potential GLP-1 Entrant

Oct 21

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 25

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 10

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Aug 18
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

May 03
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Jan 12
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Sep 29
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Jun 06
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Feb 21
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Oct 03
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Terns Pharmaceuticals: The Easy Money Has Been Made

Sep 20

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Aug 08

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Jun 14
Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Mar 16
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Nov 24
We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Aug 24
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Jun 14

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:TERN - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20262-138-108-1266
12/31/2025N/A-117-95-1008
12/31/2024N/A-99-92-808
6/30/2024N/A-96-79-79N/A
3/31/2024N/A-91-76-76N/A
12/31/2023N/A-90-67-67N/A
9/30/2023N/A-85-59-59N/A
6/30/2023N/A-72-52-52N/A
3/31/2023N/A-68-50-50N/A
12/31/2022N/A-60-49-49N/A
9/30/20221-59-49-49N/A
6/30/20221-54-44-43N/A
3/31/20221-51-41-41N/A
12/31/20211-50-42-42N/A
9/30/2021N/A-35-39-39N/A
6/30/2021N/A-35-37-37N/A
3/31/2021N/A-34-37-37N/A
12/31/2020N/A-29-30-30N/A
9/30/2020N/A-40-33-32N/A
12/31/2019N/A-69-67-66N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che TERN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che TERN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che TERN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che TERN non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che TERN non avrà alcun fatturato il prossimo anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Si prevede che TERN non sarà più redditizia tra 3 anni.


Scoprire le aziende in crescita